LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC decreased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 900,038 shares of the medical instruments supplier’s stock after selling 4,686 shares during the period. Geneva Capital Management LLC’s holdings in LeMaitre Vascular were worth $59,727,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. YHB Investment Advisors Inc. acquired a new position in shares of LeMaitre Vascular during the first quarter worth about $36,000. SRS Capital Advisors Inc. lifted its stake in LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 524 shares during the last quarter. Whitegate Investment Counselors Inc. acquired a new position in LeMaitre Vascular during the 1st quarter worth approximately $216,000. Albion Financial Group UT increased its position in shares of LeMaitre Vascular by 5.6% in the 1st quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock valued at $264,000 after purchasing an additional 212 shares during the last quarter. Finally, Personal CFO Solutions LLC raised its holdings in shares of LeMaitre Vascular by 6.4% in the 4th quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock valued at $316,000 after purchasing an additional 336 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the completion of the sale, the chief executive officer now directly owns 2,133,428 shares of the company’s stock, valued at approximately $161,500,499.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO George W. Lemaitre sold 68,906 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the completion of the sale, the chief executive officer now owns 2,133,428 shares in the company, valued at $161,500,499.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Roberts sold 5,025 shares of LeMaitre Vascular stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.62, for a total transaction of $379,990.50. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at $1,067,300.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 87,431 shares of company stock worth $6,627,520. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Up 1.9 %

LMAT traded up $1.60 during trading on Thursday, hitting $85.03. 127,404 shares of the stock were exchanged, compared to its average volume of 121,901. LeMaitre Vascular, Inc. has a 1-year low of $44.27 and a 1-year high of $85.35. The stock has a fifty day moving average price of $79.26 and a two-hundred day moving average price of $68.12. The firm has a market capitalization of $1.91 billion, a P/E ratio of 55.25, a PEG ratio of 2.52 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The business had revenue of $53.48 million for the quarter, compared to analyst estimates of $51.50 million. During the same period last year, the firm posted $0.27 earnings per share. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. Analysts predict that LeMaitre Vascular, Inc. will post 1.77 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th were issued a $0.16 dividend. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.75%. LeMaitre Vascular’s payout ratio is 42.38%.

Analyst Upgrades and Downgrades

LMAT has been the topic of several recent analyst reports. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, June 22nd. Roth Capital upgraded LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their target price for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. JMP Securities upped their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. Finally, Roth Mkm reissued a “buy” rating and set a $100.00 price objective on shares of LeMaitre Vascular in a report on Friday, May 31st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.